FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year
from Most popular articles from Medical Marketing and Media http://ift.tt/2AerkET
No comments:
Post a Comment